Inhibition of IκB Kinase-β Protects Dopamine Neurons Against Lipopolysaccharide-Induced Neurotoxicity
- 26 February 2010
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Journal of Pharmacology and Experimental Therapeutics
- Vol. 333 (3), 822-833
- https://doi.org/10.1124/jpet.110.165829
Abstract
Parkinson's disease (PD) is a progressive neurological disorder characterized by a selective loss of dopamine (DA) neurons in the substantia nigra (SN). Although current therapy can control symptoms of this disorder, there is no effective therapy available to halt its progression. Recently, neuroinflammation has been recognized as an important contributor to the pathogenesis of PD, and nuclear factor-κB (NF-κB) plays a key role in regulating neuroinflammation. Hence, the modulation of NF-κB pathway may have therapeutic potential for PD. Activation of NF-κB depends on the phosphorylation of its inhibitor, IκB, by the specific IκB kinase (IKK) subunit IKK-β. Compound A (7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-5-[(3S)-3-piperidinyl]-1, 4-dihydro-2H-pyrido[2,3-d][1,3]oxazin-2-one hydrochloride), a potent and selective inhibitor of IKK-β, has recently been reported to provide cardioprotection through specific suppression of NF-κB signaling. The present study, for the first time, elucidates neuroprotective effects of compound A. Daily subcutaneous injection of compound A (1 mg/kg) for 7 days inhibited the activation of microglia induced by nigral stereotaxic injection of lipopolysaccharide (LPS) and significantly attenuated LPS-induced loss of DA neurons in the SN. In vitro mechanistic studies revealed that neuroprotective effects of compound A were mediated by 1) suppressing the activity of microglial NADPH oxidase and decreasing the production of reactive oxygen species, and 2) inhibiting NF-κB-mediated gene transcription of various proinflammatory mediators in microglia via IKK-β suppression. These findings indicate that compound A afforded potent neuroprotection against LPS-induced neurodegeneration through selective inhibition of NF-κB activation and may be of potential benefit in the treatment of PD.Keywords
This publication has 35 references indexed in Scilit:
- Impaired Priming and Activation of the Neutrophil NADPH Oxidase in Patients with IRAK4 or NEMO DeficiencyThe Journal of Immunology, 2009
- Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-κB and JNK activation and suppression of COX-2 activityJournal of Neuroimmunology, 2007
- Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's diseaseProceedings of the National Academy of Sciences of the United States of America, 2007
- IKKβ inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injuryAmerican Journal of Physiology-Heart and Circulatory Physiology, 2007
- 3‐Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP‐elicited damage both in vivo and in vitroThe FASEB Journal, 2006
- ANP inhibits LPS-induced stimulation of rat microglial cells by suppressing NF-κB and AP-1 activationsBiochemical and Biophysical Research Communications, 2006
- Mechanisms of MAPK signalling specificityBiochemical Society Transactions, 2006
- Cellular and Molecular Mechanisms of Parkinson’s Disease: Neurotoxins, Causative Genes, and Inflammatory CytokinesCellular and Molecular Neurobiology, 2006
- Circuitry of nuclear factor κB signalingImmunological Reviews, 2006
- TNF-α promotes a stop signal that inhibits neutrophil polarization and migration via a p38 MAPK pathwayJournal of Leukocyte Biology, 2005